

## Special Issue

# Pharmacogenomics of Oncology Therapies

### Message from the Guest Editor

Background: Precision medicine in the form of pharmacogenomics (PGx) is an ever-increasing area of practice in the oncology care setting. Many examples exist as to how genetic polymorphisms influence a drug's effect by altering its PK-PD. However for cancer therapies, which are often limited by a narrow therapeutic index and inter-individual variation in response, a better understanding of how genetic factors influence drug metabolism/transport and consequent treatment outcomes is still critically needed. Aim and Scope: The aim of this Special Issue is to provide recent trends, updates, and progress on how PGx, on both the basic science and clinical level, is improving cancer care. What kind of papers we are soliciting: We are inviting the submission of original articles to this Special Issue of *JPM* that covers the whole spectrum of PGx of oncology therapies and adjuvant drugs used in the cancer care setting – from basic science to case reports and full clinical studies, and relevant review articles.

### Guest Editor

Dr. Alan L. Myers

Department of Diagnostic and Biomedical Sciences, University of Texas Health Science Center Houston, Houston, TX, USA

### Deadline for manuscript submissions

closed (1 November 2021)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/42959](https://mdpi.com/si/42959)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jpm)

[jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).